Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Regeneron Pharmaceuticals Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Return on Sales
Gross profit margin 86.16% 85.96% 86.42% 86.96% 87.18% 85.39% 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05%
Operating profit margin 30.85% 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Net profit margin 30.14% 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Return on Investment
Return on equity (ROE) 15.22% 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Return on assets (ROA) 11.95% 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Regeneron Pharmaceuticals Inc. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 but then slightly improved from Q3 2023 to Q4 2023.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Regeneron Pharmaceuticals Inc. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Regeneron Pharmaceuticals Inc. net profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Regeneron Pharmaceuticals Inc. ROE deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
ROA A profitability ratio calculated as net income divided by total assets. Regeneron Pharmaceuticals Inc. ROA deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Gross Profit Margin

Regeneron Pharmaceuticals Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Gross profit 2,917,300 2,926,300 2,753,200 2,704,600 2,873,800 2,618,400 2,560,100 2,560,200 3,969,100 2,999,600 4,444,800 2,220,700 2,069,800 2,020,000 1,676,500 1,610,900 1,945,600 1,821,800 1,781,200 1,532,600
Revenues 3,434,300 3,362,700 3,158,100 3,162,100 3,414,400 2,936,200 2,857,200 2,965,100 4,951,700 3,452,800 5,138,500 2,528,700 2,422,900 2,294,000 1,952,000 1,828,200 2,169,500 2,048,400 1,933,700 1,711,800
Profitability Ratio
Gross profit margin1 86.16% 85.96% 86.42% 86.96% 87.18% 85.39% 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 62.42% 65.76% 68.91% 69.43% 70.00% 69.62% 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64%
Amgen Inc. 68.60% 72.35% 72.87% 73.65% 74.17% 73.99% 74.00% 73.30% 73.44% 74.00% 73.97% 74.37% 74.59% 75.55% 77.15% 78.90% 80.38%
Bristol-Myers Squibb Co. 76.24% 76.54% 77.01% 77.68% 78.04% 78.82% 79.13% 79.62% 78.57% 76.92% 75.88% 74.42% 72.31% 71.18% 69.47% 68.02% 69.10%
Eli Lilly & Co. 79.25% 78.67% 77.77% 77.67% 76.77% 75.61% 75.98% 74.40% 74.18% 74.85% 74.27% 75.88% 77.66% 78.26% 78.67% 79.22% 78.85%
Gilead Sciences Inc. 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50% 75.56% 80.23% 79.90% 80.32% 81.23% 78.72% 78.25% 79.06% 78.86%
Johnson & Johnson 68.82% 67.51% 67.09% 66.88% 67.26% 67.43% 67.86% 67.97% 68.16% 67.51% 67.00% 66.24% 65.58% 65.68% 65.66% 66.15% 66.42%
Merck & Co. Inc. 73.17% 72.86% 72.96% 72.43% 70.63% 70.49% 70.41% 70.72% 72.02% 67.95% 67.48% 66.99% 67.74% 71.23% 70.06% 70.11% 69.87%
Pfizer Inc. 57.34% 60.55% 69.42% 68.54% 65.77% 65.53% 62.18% 60.35% 62.08% 65.28% 70.96% 76.46% 79.26% 80.47% 80.19% 80.03% 80.25%
Thermo Fisher Scientific Inc. 39.90% 39.87% 39.75% 40.28% 42.24% 44.42% 46.63% 48.37% 50.08% 51.05% 51.29% 51.47% 49.67% 47.31% 45.39% 44.30% 44.35%
Vertex Pharmaceuticals Inc. 87.21% 87.80% 87.92% 88.04% 87.90% 88.00% 88.13% 87.95% 88.06% 87.94% 87.89% 88.06% 88.14% 88.01% 87.71% 87.24% 86.84%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Gross profit margin = 100 × (Gross profitQ4 2023 + Gross profitQ3 2023 + Gross profitQ2 2023 + Gross profitQ1 2023) ÷ (RevenuesQ4 2023 + RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023)
= 100 × (2,917,300 + 2,926,300 + 2,753,200 + 2,704,600) ÷ (3,434,300 + 3,362,700 + 3,158,100 + 3,162,100) = 86.16%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Regeneron Pharmaceuticals Inc. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 but then slightly improved from Q3 2023 to Q4 2023.

Operating Profit Margin

Regeneron Pharmaceuticals Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Income from operations 972,900 1,111,000 1,016,500 946,700 1,146,800 1,223,700 1,109,900 1,258,500 2,639,700 1,847,200 3,347,200 1,112,700 1,167,000 1,053,100 656,400 700,100 675,700 738,500 315,600 480,000
Revenues 3,434,300 3,362,700 3,158,100 3,162,100 3,414,400 2,936,200 2,857,200 2,965,100 4,951,700 3,452,800 5,138,500 2,528,700 2,422,900 2,294,000 1,952,000 1,828,200 2,169,500 2,048,400 1,933,700 1,711,800
Profitability Ratio
Operating profit margin1 30.85% 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 23.49% 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03%
Amgen Inc. 29.35% 34.55% 37.50% 36.07% 38.57% 39.31% 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57%
Bristol-Myers Squibb Co. 16.18% 16.96% 17.29% 18.13% 17.96% 19.04% 18.19% 16.79% 15.91% -15.73% -17.02% -19.19% -21.60% 9.27% 11.67% 16.30% 22.62%
Eli Lilly & Co. 18.92% 18.42% 24.17% 22.45% 24.97% 24.65% 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29%
Gilead Sciences Inc. 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Johnson & Johnson 24.90% 25.19% 25.26% 25.04% 24.63% 23.89% 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15%
Merck & Co. Inc. 3.92% 13.08% 10.34% 27.85% 30.27% 30.66% 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77%
Pfizer Inc. 0.38% 13.44% 27.69% 34.30% 34.83% 33.59% 30.37% 26.12% 23.91% 24.67% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46%
Thermo Fisher Scientific Inc. 16.00% 15.81% 15.42% 16.29% 18.69% 20.54% 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99%
Vertex Pharmaceuticals Inc. 38.83% 40.16% 41.72% 43.93% 48.23% 47.72% 48.85% 36.93% 36.73% 37.17% 33.93% 47.14% 46.03% 44.43% 38.67% 34.05% 28.77%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Operating profit margin = 100 × (Income from operationsQ4 2023 + Income from operationsQ3 2023 + Income from operationsQ2 2023 + Income from operationsQ1 2023) ÷ (RevenuesQ4 2023 + RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023)
= 100 × (972,900 + 1,111,000 + 1,016,500 + 946,700) ÷ (3,434,300 + 3,362,700 + 3,158,100 + 3,162,100) = 30.85%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Regeneron Pharmaceuticals Inc. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Net Profit Margin

Regeneron Pharmaceuticals Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Net income 1,159,600 1,007,800 968,400 817,800 1,197,100 1,315,700 852,100 973,500 2,229,000 1,632,200 3,098,900 1,115,200 1,149,200 842,100 897,300 624,600 792,000 669,600 193,100 461,100
Revenues 3,434,300 3,362,700 3,158,100 3,162,100 3,414,400 2,936,200 2,857,200 2,965,100 4,951,700 3,452,800 5,138,500 2,528,700 2,422,900 2,294,000 1,952,000 1,828,200 2,169,500 2,048,400 1,933,700 1,711,800
Profitability Ratio
Net profit margin1 30.14% 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 8.95% 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69%
Amgen Inc. 24.96% 29.52% 31.52% 31.77% 26.42% 27.88% 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32%
Bristol-Myers Squibb Co. 17.83% 18.44% 17.62% 15.95% 13.71% 14.29% 14.04% 13.31% 15.08% -11.89% -11.44% -14.53% -21.20% -0.11% -1.61% 3.08% 13.15%
Eli Lilly & Co. 15.36% 15.55% 22.01% 20.54% 21.88% 20.63% 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27%
Gilead Sciences Inc. 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Johnson & Johnson 41.28% 36.32% 13.35% 13.22% 18.90% 19.95% 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42%
Merck & Co. Inc. 0.61% 7.77% 5.34% 22.52% 24.49% 25.88% 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01%
Pfizer Inc. 3.62% 15.29% 27.55% 31.25% 31.27% 29.81% 28.94% 27.01% 27.04% 28.77% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45%
Thermo Fisher Scientific Inc. 13.99% 13.68% 13.14% 13.75% 15.47% 15.92% 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47%
Vertex Pharmaceuticals Inc. 36.68% 35.94% 35.40% 35.40% 37.20% 37.62% 38.26% 30.84% 30.92% 30.52% 29.80% 43.06% 43.70% 44.91% 38.51% 31.35% 28.27%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Net profit margin = 100 × (Net incomeQ4 2023 + Net incomeQ3 2023 + Net incomeQ2 2023 + Net incomeQ1 2023) ÷ (RevenuesQ4 2023 + RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023)
= 100 × (1,159,600 + 1,007,800 + 968,400 + 817,800) ÷ (3,434,300 + 3,362,700 + 3,158,100 + 3,162,100) = 30.14%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Regeneron Pharmaceuticals Inc. net profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Return on Equity (ROE)

Regeneron Pharmaceuticals Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Net income 1,159,600 1,007,800 968,400 817,800 1,197,100 1,315,700 852,100 973,500 2,229,000 1,632,200 3,098,900 1,115,200 1,149,200 842,100 897,300 624,600 792,000 669,600 193,100 461,100
Stockholders’ equity 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Profitability Ratio
ROE1 15.22% 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Benchmarks
ROE, Competitors2
AbbVie Inc. 46.94% 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30%
Amgen Inc. 107.78% 98.82% 117.67% 148.04% 178.97% 187.11% 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07%
Bristol-Myers Squibb Co. 27.27% 28.57% 24.91% 22.97% 20.37% 20.44% 20.30% 19.79% 19.46% -14.52% -13.80% -16.54% -23.84% -0.09% -1.15% 1.91% 6.66%
Eli Lilly & Co. 48.65% 44.46% 58.73% 50.82% 58.64% 59.91% 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09%
Gilead Sciences Inc. 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Johnson & Johnson 51.11% 48.61% 17.37% 17.95% 23.36% 25.68% 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42%
Merck & Co. Inc. 0.97% 11.17% 8.04% 27.82% 31.57% 34.32% 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99%
Pfizer Inc. 2.38% 10.81% 21.68% 28.77% 32.79% 32.14% 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77%
Thermo Fisher Scientific Inc. 12.83% 13.11% 13.08% 14.26% 15.80% 16.15% 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45%
Vertex Pharmaceuticals Inc. 20.59% 21.01% 21.75% 22.59% 23.88% 25.12% 26.77% 22.47% 23.19% 22.83% 21.66% 30.76% 31.22% 33.08% 27.67% 23.38% 19.34%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
ROE = 100 × (Net incomeQ4 2023 + Net incomeQ3 2023 + Net incomeQ2 2023 + Net incomeQ1 2023) ÷ Stockholders’ equity
= 100 × (1,159,600 + 1,007,800 + 968,400 + 817,800) ÷ 25,973,100 = 15.22%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Regeneron Pharmaceuticals Inc. ROE deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Return on Assets (ROA)

Regeneron Pharmaceuticals Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Net income 1,159,600 1,007,800 968,400 817,800 1,197,100 1,315,700 852,100 973,500 2,229,000 1,632,200 3,098,900 1,115,200 1,149,200 842,100 897,300 624,600 792,000 669,600 193,100 461,100
Total assets 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800
Profitability Ratio
ROA1 11.95% 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%
Benchmarks
ROA, Competitors2
AbbVie Inc. 3.61% 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84%
Amgen Inc. 6.91% 8.36% 8.84% 8.92% 10.06% 10.73% 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13%
Bristol-Myers Squibb Co. 8.43% 9.08% 8.52% 7.75% 6.53% 6.80% 6.59% 6.07% 6.40% -4.87% -4.58% -5.53% -7.61% -0.04% -0.44% 0.74% 2.65%
Eli Lilly & Co. 8.19% 8.61% 11.85% 10.70% 12.62% 12.71% 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17%
Gilead Sciences Inc. 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%
Johnson & Johnson 20.98% 20.85% 6.81% 6.49% 9.57% 10.94% 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59%
Merck & Co. Inc. 0.34% 4.32% 2.98% 12.09% 13.30% 14.25% 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66%
Pfizer Inc. 0.94% 4.87% 9.75% 14.85% 15.91% 15.32% 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72%
Thermo Fisher Scientific Inc. 6.07% 6.12% 6.08% 6.36% 7.15% 7.77% 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33%
Vertex Pharmaceuticals Inc. 15.92% 15.97% 16.54% 17.18% 18.30% 19.59% 20.50% 17.19% 17.44% 17.25% 16.30% 22.80% 23.07% 23.81% 20.37% 16.99% 14.15%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
ROA = 100 × (Net incomeQ4 2023 + Net incomeQ3 2023 + Net incomeQ2 2023 + Net incomeQ1 2023) ÷ Total assets
= 100 × (1,159,600 + 1,007,800 + 968,400 + 817,800) ÷ 33,080,200 = 11.95%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Regeneron Pharmaceuticals Inc. ROA deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.